MOv19-BBζ showed improved T cell persistence and potent antitumor activity.76 The first-in-human Phase 1 clinical trial was launched to evaluate the safety of MOv19-BBζ CAR T cells in patients with FRα-expressing recurrent high grade serous ovarian cancer (NCT03585764).49,77 Pilot studies of anti-FRα CAR constructs are being conducted against gastric cancer and triple-negative breast cancer.78,79. Here, FOLR1 is linked to ovarian serous adenocarcinoma.